tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Christopher Marai, 145 are a BUY (91.19%), 5 are a HOLD (3.14%), 9 are a SELL (5.66%).
Analyst Christopher Marai, carries an average stock price target met ratio of 56.98% that have a potential upside of 68.76% achieved within 413 days. Previously, Christopher Marai worked at PIPER SANDLER, NOMURA, RAYMOND JAMES, OPPENHEIMER, BAIRD.
Christopher Marai’s has documented 326 price targets and ratings displayed on 30 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 14-Feb-2025.
Analyst best performing recommendations are on DCPH (DECIPHERA PHARMACEUTICALS LLC).
The best stock recommendation documented was for DCPH (DECIPHERA PHARMACEUTICALS LLC) at 10/23/2017. The price target of $57 was fulfilled within 31 days with a profit of $36.21 (174.17%) receiving and performance score of 56.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 20-Sep-2022
$345
$112.32 (48.27%)
$350
Buy Since 15-May-2025
$369
$136.32 (58.59%)
$375
10 days ago
(30-Sep-2026)
9/12 (75%)
$122.26 (49.55%)
30
Buy Since 12-Feb-2021
$455
$222.32 (95.55%)
$455
19 days ago
(21-Sep-2026)
24/43 (55.81%)
$210.68 (86.23%)
682
Hold Since 31-Mar-2026
$260
$27.32 (11.74%)
$330
1 months 2 days ago
(08-Sep-2026)
3/3 (100%)
$-0.1 (-0.04%)
6
Buy Since 21-Mar-2025
$318
$85.32 (36.67%)
$583
1 months 21 days ago
(19-Aug-2026)
34/36 (94.44%)
$75.39 (31.07%)
273
